Target intelligence / Profile preview

60S ribosomal protein L22 (RPL22)

Target
RPL22
Molecular classification
Other (ribosomal protein), Structural constituent of ribosome
01

Overview

60S ribosomal protein L22 (RPL22) is a structural protein component of the large (60S) subunit of the eukaryotic ribosome and is integral to protein synthesis in the cytoplasm[3][5]. It is part of the L22E family, interacts directly with ribosomal RNA (notably 23S/28S rRNA), and has the ability to bind certain viral RNAs such as those from Epstein-Barr virus (EBV)[3]. In mice, RPL22 is essential for normal T and B cell development and can regulate its own function as well as that of the closely related RPL22-like1 (RPL22L1), which can compensate for its absence to some extent[1]. Aside from its core structural role, RPL22 may participate in the regulation of RNA stability, telomerase activity, and be involved in extra-ribosomal activities relevant to immune function and disease development[1][3]. There is no evidence that RPL22 functions as a classical drug target, receptor, enzyme, or transporter; its medical significance derives from its indirect roles in disease pathogenesis.

Other names
Large ribosomal subunit protein eL22EBER-associated proteinEpstein-Barr virus (EBV) small RNA-associated proteinHeparin-binding protein HBp15HBP15/L22EAPL22eL22
02

Mechanism of action

Not applicable (no drugs targeting this protein directly; antibiotics act on ribosomes broadly, but RPL22 is not a common primary target)

03

Biological functions

Protein synthesisStructural constituent of ribosomeRNA bindingTranslation regulationHeparin binding
04

Disease associations

Cancer (alterations/mutations in ribosomal proteins including RPL22 have been implicated)Immune system function abnormalitiesInfection (notably in EBV biology)Other
05

Safety considerations

Loss of function can impair immune cell (T and B cell) development, but no specific drug safety concerns since not a drug target

Beyond the preview

Go deeper on 60S ribosomal protein L22 (RPL22).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 60S ribosomal protein L22 (RPL22).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call